PROs Support Switching to Camizestrant Plus CDK4/6 Inhibitor for HR-positive, HER2-negative ABC and Emergent ESR1 Mutations During First-Line Endocrine-Based Therapy By Ogkologos - November 10, 2025 169 0 Facebook Twitter Google+ Pinterest WhatsApp Patient-reported outcomes from the SERENA-6 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR EMA Recommends Extension of Therapeutic Indications for Cabozantinib April 29, 2022 Cancer in My Community: The Role of Cancer Screening in Guatemala November 5, 2020 Overall Breast Cancer Incidence Down Since 1999, Rates Increase for Women... January 18, 2022 Couple Buys Customized SUV To Give Free Rides To Critically Ill... September 11, 2019 Load more HOT NEWS ΚΑΡΚΙΝΟΣ ΤΟΥ ΜΑΣΤΟΥ Early Signs of Efficacy of New Targeted Agents and Immunotherapies Reported... Intensive Program Helps People Being Screened for Lung Cancer Quit Smoking Palliative and Supportive Care for Children With Cancer: An Expert Perspective
